Men have bone loss to worry about as well and this recent study shows there might be some hope while undergoing cancer treatment with less bone loss during the therapy with better bone mineral density. Similar results for women undergoing cancer treatment for breast cancer were also reported. BD
During the 36-month evaluation period, men receiving denosumab experienced less than half the incidence of new vertebral fractures (a secondary endpoint) compared with those receiving placebo, a statistically significant finding. Furthermore, in the denosumab arm there were fewer non-vertebral fractures over the 36-month period.
0 comments :
Post a Comment